Zobrazeno 1 - 4
of 4
pro vyhledávání: '"785"'
Publikováno v:
Blood. 132:4849-4849
Background: Newly diagnosed acute myeloid leukemia (ND AML) patients (pts) ineligible for intensive chemotherapy have limited treatment options. Most commonly used low intensity regimens are azacitidine (AZA), decitabine (DEC), or low-dose cytarabine
Publikováno v:
Blood. 136:21-22
Introduction Chimeric Antigen Receptor (CAR) T cell therapy has improved outcomes for relapsed and/or refractory (r/r) B cell lymphomas. Bridging therapy might be needed in some patients for disease control while CAR T product is being produced. Radi
Autor:
Jürgen Krauter, Mark Ringhoffer, Arnold Ganser, Brigitte Schlegelberger, Daniela Späth, Marie von Lilienfeld-Toal, David Nachbaur, Hartmut Döhner, Veronica Teleanu, Gerhard Held, Michael Lübbert, Hans Martin, Verena I. Gaidzik, Gudrun Göhring, Sabine Kayser, Patricia Erdmann, Wolfgang Herr, Ulrich Germing, Mathias J. Rummel, Helmut R. Salih, Claus-Henning Köhne, Katharina Götze, H Salwender, Thomas Fischer, Richard F. Schlenk, Peter Paschka, Heinz A. Horst, Konstanze Döhner
Publikováno v:
Blood. 120:785-785
Abstract 785 Background: FLT3 internal tandem duplications (FLT3-ITD) occur in about 25% of acute myeloid leukemia (AML), are associated with cooperating gene mutations (NPM1, DNMT3A), and confer an adverse prognosis. Several studies have indicated t
Publikováno v:
Blood. 114:785-785
Abstract 785 Introduction: The ability of allogeneic T cells to effect anti tumor responses had greatly improved the outcome of malignant EBV-associated lymphoproliferations. But high doses of DLI (donor lymphocyte infusion) could arise severe GVHD (